Increased serum levels of adhesion molecules ICAM-1 and VCAM-1 in systemic sclerosis are not specific for pulmonary manifestations.

Authors:
Vivek Thakkar
Vivek Thakkar
St Vincent's Hospital Melbourne
Australia
Karen A Patterson
Karen A Patterson
Flinders University
Bedford Park | Australia
Wendy Stevens
Wendy Stevens
University of the Witwatersrand
South Africa
Michelle Wilson
Michelle Wilson
Auckland City Hospital
Auckland | New Zealand
Janet Roddy
Janet Roddy
St Vincent's Hospital Melbourne
Australia
Joanne Sahhar
Joanne Sahhar
The University of Melbourne
Australia
Susanna Proudman
Susanna Proudman
Royal Adelaide Hospital
Adelaide | Australia
Pravin Hissaria
Pravin Hissaria
Royal Adelaide Hospital
Australia

Clin Rheumatol 2018 Jun 23;37(6):1563-1571. Epub 2018 Apr 23.

Department of Rheumatology, St Vincent's Hospital (Melbourne), 41 Parade, Fitzroy, VIC, 3065, Australia.

Studies suggest elevated serum intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) levels may be markers of pulmonary arterial hypertension in systemic sclerosis (SSc-PAH). We sought to evaluate whether ICAM-1 and VCAM-1 levels are useful screening biomarkers for incident SSc-PAH. In this cross-sectional study, four groups were selected from the Australian Scleroderma Cohort Study: group 1 (n = 15) had definite PAH; group 2 (n = 19) had interstitial lung disease (ILD); group 3 (n = 30) were SSc-controls; and group 4 (n = 34) were healthy controls. Serum ICAM-1 and VCAM-1 levels were measured using the Millipore Milliplex MAP Human 2-Plex Panel. There were no differences in ICAM-1 levels in the PAH versus ILD group (263.0 ± 85.4 vs 380.4 ± 168.3 ng/mL, p = 0.136), SSc-controls (263.0 ± 85.4 vs 253.1 ± 98.0 ng/mL, p = 1.00), or healthy controls (263.0 ± 85.4 vs 201.8 ± 57.2 ng/mL, p = 0.093). Similarly, there were no differences in VCAM-1 level in PAH versus ILD groups (1476.2 ± 434.9 vs 1424.8 ± 527.6 ng/mL, p = 1.00) and SSc-controls (1476.2 ± 434.9 vs 1409.5 ± 341.1 ng/mL, p = 1.00). SSc subjects had significantly higher levels of ICAM-1 (297.4 ± 134.0 vs 201.8 ± 57.2 ng/mL, p < 0.0001) and VCAM-1 compared to healthy controls (1432.7 ± 427.4 vs 1125.6 ± 273.4 ng/mL, p < 0.0001). Neither ICAM-1 nor VCAM-1 is a specific screening biomarker of SSc-PAH. Instead, increased levels of these adhesion molecules in SSc, irrespective of pulmonary complications, suggest that they may play a role in SSc pathogenesis.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-018-4081-7DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
June 2018
7 Reads

Publication Analysis

Top Keywords

vcam-1 levels
12
icam-1 vcam-1
12
pah versus
8
systemic sclerosis
8
healthy controls
8
ild group
8
versus ild
8
adhesion molecule-1
8
icam-1
6
levels
6
vcam-1
5
group
5
vcam-1 level
4
n = 19 interstitial
4
group n = 19
4
ild groups
4
level pah
4
disease ild
4
differences vcam-1
4
group n = 30
4

References

(Supplied by CrossRef)
Article in Annu Rev Pathol
TR Katsumoto et al.
Annu Rev Pathol 2011
Article in Clin Rev Allergy Immunol
M Geyer et al.
Clin Rev Allergy Immunol 2010
Article in N Engl J Med
A Gabrielli et al.
N Engl J Med 2009
Article in Arthritis Care Res (Hoboken)
L Chung et al.
Arthritis Care Res (Hoboken) 2014
Article in Best Pract Res Clin Rheumatol
V Thakkar et al.
Best Pract Res Clin Rheumatol 2016
Article in Nat Rev Cardiol
EM Lau et al.
Nat Rev Cardiol 2015
Article in PLoS One
SA Pendergrass et al.
PLoS One 2010
Article in Arthritis Rheum
CF Mojcik et al.
Arthritis Rheum 1997
Article in J Interf Cytokine Res
G Krishnaswamy et al.
J Interf Cytokine Res 1999
Article in Arthritis Rheum
BW Needleman et al.
Arthritis Rheum 1990
Article in Pathobiology
MM Cho et al.
Pathobiology 1994

Similar Publications